Rhodopsin consists of an apoprotein (opsin) covalently bound to 11-cis-retinal, a vitamin A derivative . In Poecilia reticulata, this protein facilitates scotopic (low-light) vision. Recombinant versions are produced to investigate its biophysical properties, misfolding mechanisms (linked to retinal dystrophies), and therapeutic interventions .
Recombinant Poecilia reticulata rhodopsin is typically expressed in heterologous systems like E. coli or mammalian cells. A generalized protocol includes:
Retinitis Pigmentosa (RP): Class II mutations (e.g., P23H) cause ER retention and activate the unfolded protein response (UPR), leading to photoreceptor apoptosis . Recombinant mutants enable studies on proteostasis and therapeutic chaperones (e.g., YC-001) .
Constitutive Activity: Mutants like G90D exhibit light-independent signaling, modeling congenital stationary night blindness .
Gene Therapy: AAV vectors deliver wild-type RHO to suppress dominant-negative mutants .
Pharmacological Chaperones: Compounds like 9-cis-retinal stabilize misfolded rhodopsin, improving trafficking to photoreceptor outer segments .
Misfolding: Mutations disrupt disulfide bonding (e.g., Cys185–Cys187 in misfolded RP mutants), reducing retinal binding .
Low Stability: Misfolded rhodopsin degrades rapidly via the ubiquitin-proteasome system .
Species-Specific Variations: Post-translational modifications (e.g., glycosylation) differ across species, affecting functional studies .